Trial Profile
A Double-Blind, Randomized, Placebo-Controlled Trial of Xenon Inhalation for Treatment of Patients With Posttraumatic Stress Disorder
Status:
Not yet recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 06 Mar 2023
Price :
$35
*
At a glance
- Drugs NBTX 001 (Primary)
- Indications Post-traumatic stress disorders
- Focus Therapeutic Use
- Sponsors Nobilis Therapeutics
- 02 Mar 2021 Planned initiation date changed from 1 Dec 2020 to 31 May 2021.
- 10 Sep 2020 Planned initiation date changed from 1 Jul 2020 to 1 Dec 2020.
- 28 Feb 2020 Planned End Date changed from 1 Dec 2020 to 1 Jul 2021.